Direct RNA Opportunity Helicos offers direct RNA sequencing and true single molecule sequencing, along with a sequencing services program. This enables labs to obtain amplification-free, direct measurements of RNA and DNA, addressing biases common in traditional methods. Target academic and biotech customers seeking outsourcing options or direct measurement capabilities, with opportunities to upsell platform access, reagents, and software licenses.

Platform and Consumables The HeliScope system comprises the sequencer, analysis engine, and sample loader with novel reagent packaging and intuitive software that automates tracking of consumables. This setup supports sales of ongoing consumables, maintenance, and software updates, as well as training and onboarding services to new users.

Early Leader Positioning As the first mover in single-molecule sequencing, Helicos has a unique market narrative. This can be leveraged for licensing, co-development, or distribution partnerships with larger biotech firms seeking early access to unique capabilities, especially for direct RNA and amplification-free workflows.

Strategic Partnerships With modest revenue and a lean team, the company benefits from channel partnerships, CRO collaborations, or licensing deals that can extend market reach without heavy internal expansion. Target prospects include academic consortia, government labs, and mid-sized biotech companies seeking to augment sequencing capabilities.

US Biotech Hub Proximity Based in Lexington, Massachusetts, Helicos sits in a dense biotech ecosystem near top universities and pharma companies. This geography supports targeted business development, pilot studies, regional partnerships, and rapid service deployment for local customers.